We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
10 April 2019
On 1 February 2019 the Ontario Ministry of Health and Long-Term Care announced that CWC Pharmacies (Ontario) Ltd (Costco Pharmacies), a subsidiary of Costco, was ordered to pay an administrative monetary penalty of C$7.25 million for accepting payments from certain generic manufacturers which violated the prohibition on drug rebates.
In Ontario, the Ontario Drug Benefit Act and the Drug Interchangeability and Dispensing Fee Act prohibit pharmacies from accepting rebates from drug manufacturers for drugs that qualify as a listed drug product or as an interchangeable product on the Ontario Drug Benefit Formulary/Comparative Drug Index. The rebate order states that 'for' means that the benefit is linked directly or indirectly to listed or interchangeable products sold or offered for sale to the pharmacy. The definition of 'rebate', which is set out in the legislation, limits the permissible payments from a manufacturer to a pharmacy to only those made in accordance with ordinary commercial terms (ie, distribution service fee, volume discount and prompt payment discount). The ministry concluded that the fee-for-service payments received by Costco Pharmacies for advertising services were not provided in accordance with ordinary commercial terms and accordingly violated the prohibition on rebates. The C$7.25 million administrative monetary penalty imposed on Costco Pharmacies equals the amount in prohibited payments it received for the advertising services and follows disciplinary action taken by the Ontario College of Pharmacists in 2018 against two directors of Costco Pharmacies relating to this rebate activity.
The rebate order is important because it marks the first enforcement action on rebates taken by the ministry in almost a decade. The announcement specifically states that both the announcement and the rebate order are intended to "serve as a guide for the pharmaceutical industry for complying with the rebate prohibition".
For further information on this topic please contact Alice Tseng or Eleanor Wilson at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (email@example.com or firstname.lastname@example.org). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.